Skip to content
NewsBlazeIN – Lifestyle
Author:
ADARx Pharmaceuticals Inc.
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
October 1, 2026
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
September 24, 2026